Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice von Chang, Tiffany, Krisman, Kimberly, Theobald, Emily Harding, Xu, Jin, Akutagawa, Jon, Lauchle, Jennifer O, Kogan, Scott, Braun, Benjamin S, Shannon, Kevin

Volltext

Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras von Coakley, Kristen M, Shannon, Kevin, Li, Qing, Warner, Kegan, Przybranowski, Sally, Akagi, Keiko, Krisman, Kimberly, Kogan, Scott C, Parada, Luis, Diaz-Flores, Ernesto, Gorman, Matthew, Roose, Jeroen P, Kim, Doris, Bonifas, Jeannette M, Crone, Michael, Jenkins, Nancy A, Wolff, Linda, Lauchle, Jennifer O, Copeland, Neal G, Sebolt-Leopold, Judith, Tran, Mary, Le, Doan T

Volltext

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder von Le, Doan T., Kong, Namie, Zhu, Yuan, Lauchle, Jennifer O., Aiyigari, Abigail, Braun, Benjamin S., Wang, Endi, Kogan, Scott C., Le Beau, Michelle M., Parada, Luis, Shannon, Kevin M.

Volltext

Inherited predispositions and hyperactive Ras in myeloid leukemogenesis von Lauchle, Jennifer O., Braun, Benjamin S., Loh, Mignon L., Shannon, Kevin

Volltext

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors von Dolly, Saoirse O, Wagner, Andrew J, Bendell, Johanna C, Kindler, Hedy L, Krug, Lee M, Seiwert, Tanguy Y, Zauderer, Marjorie G, Lolkema, Martijn P, Apt, Doris, Yeh, Ru-Fang, Fredrickson, Jill O, Spoerke, Jill M, Koeppen, Hartmut, Ware, Joseph A, Lauchle, Jennifer O, Burris, 3rd, Howard A, de Bono, Johann S

Volltext

A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study) von Makker, Vicky, Recio, Fernando O., Ma, Ling, Matulonis, Ursula A., Lauchle, Jennifer O., Parmar, Hema, Gilbert, Houston N., Ware, Joseph A., Zhu, Rui, Lu, Shan, Huw, Ling‐Yuh, Wang, Yulei, Koeppen, Hartmut, Spoerke, Jill M., Lackner, Mark R., Aghajanian, Carol A.

Volltext

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors von Infante, Jeffrey R, Hollebecque, Antoine, Postel-Vinay, Sophie, Bauer, Todd M, Blackwood, Elizabeth M, Evangelista, Marie, Mahrus, Sami, Peale, Franklin V, Lu, Xuyang, Sahasranaman, Srikumar, Zhu, Rui, Chen, Yuan, Ding, Xiao, Murray, Elaine R, Schutzman, Jennifer L, Lauchle, Jennifer O, Soria, Jean-Charles, LoRusso, Patricia M

Volltext

A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies von Maertens, Ophélia, McCurrach, Mila E, Braun, Benjamin S, De Raedt, Thomas, Epstein, Inbal, Huang, Tannie Q, Lauchle, Jennifer O, Lee, Hyerim, Wu, Jianqiang, Cripe, Timothy P, Clapp, D Wade, Ratner, Nancy, Shannon, Kevin, Cichowski, Karen

Volltext

Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22 von Curtiss, Nicole P., Bonifas, Jeannette M., Lauchle, Jennifer O., Balkman, Jason D., Kratz, Christian P., Emerling, Brooke M., Green, Eric D., Le Beau, Michelle M., Shannon, Kevin M.

Volltext

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice von Chang, Tiffany, Krisman, Kimberly, Theobald, Emily Harding, Xu, Jin, Akutagawa, Jon, Lauchle, Jennifer O, Kogan, Scott, Braun, Benjamin S, Shannon, Kevin

Volltext

β common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice von Kim, Andrew, Morgan, Kelly, Hasz, Diane E., Wiesner, Stephen M., Lauchle, Jennifer O., Geurts, Jennifer L., Diers, Miechaleen D., Le, Doan T., Kogan, Scott C., Parada, Luis F., Shannon, Kevin, Largaespada, David A.

Volltext

Somatic inactivation of Nfl in hematopoietic cells results in a progressive myeloproliferative disorder von LE, Doan T, NAMIE KONG, SHANNON, Kevin M, YUAN ZHU, LAUCHLE, Jennifer O, AIYIGARI, Abigail, BRAUN, Benjamin S, ENDI WANG, KOGAN, Scott C, LE BEAU, Michelle M, PARADA, Luis

Volltext

Abstract B03: Pharmacodynamic biomarker evaluation in phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors von Nakanishi, Yoshito, Spoerke, Jill M., Derynck, Mika, Lauchle, Jennifer O., Koeppen, Hartmut, Fredrickson, Jill, Ware, Joseph, Hampton, Garret, Yan, Yibing, Lackner, Mark R.

Volltext

Abstract A03: Comprehensive predictive biomarker evaluation in two phase II clinical trials of the PI3K/mTOR inhibitor GDC-0980 in metastatic renal cell carcinoma and advanced endo... von Spoerke, Jill M., Makker, Vicky, Aghajanian, Carol, Thomas, Powles, Motzer, Robert J., Lauchle, Jennifer O., Parmar, Hema, Gilbert, Houston, Lin, Wei, O'Keeffe, Bridget, Byrtek, Michelle, Koeppen, Hartmut, Wang, Yulei, Lu, Shan, Huw, Ling-Yuh, Hampton, Garret M., Lackner, Mark R.

Volltext

Abstract B153: A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTOR inhibitor GDC-0980 administered once weekly (QW) von Hollebecque, Antoine, Clamp, Andrew, Horsley, Laura, Morgan, Jeffrey A., Bahleda, Rastilav, George, Suzanne, Shaw, Danielle, Lauchle, Jennifer O., Ware, Joseph, Desai, Rupal, Wu, Jenny, Fu, Ling, Jayson, Gordon C., Soria, Jean-Charles, Wagner, Andrew J.

Volltext

Intracellular Signals as Molecular Biomarkers for Therapeutic Responses in Kras Mutant Myeloid Cells von Diaz-Flores, Ernesto, VanMeter, Margaret, Lauchle, Jennifer O., Braun, Benjamin S., Shannon, Kevin M.

Volltext

Mutations That Cooperate with Nf1 Inactivation in Leukemogenesis Influence Therapeutic Response to MEK Inhibition von Lauchle, Jennifer O., Le, Doan T., Kim, Doris, Akagi, Keiko, Gorman, Matthew F., Tran, Mary, Sebolt-Leopold, Judith, Wolff, Linda, Parada, Luis F., Jenkins, Nancy, Copeland, Neal, Shannon, Kevin M.

Volltext

β common receptor inactivation attenuates myeloproliferative disease in Nfl mutant mice von KIM, Andrew, MORGAN, Kelly, SHANNON, Kevin, LARGAESPADA, David A, HASZ, Diane E, WIESNER, Stephen M, LAUCHLE, Jennifer O, GEURTS, Jennifer L, DIERS, Miechaleen D, LE, Doan T, KOGAN, Scott C, PARADA, Luis F

Volltext

COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER von MAMOUNAS Michael Joseph, HUANG Jian, O''hara LAUCHLE Jennifer, SCHUTZMAN Jennifer Lee, FRIEDMAN Lori Sickels

Volltext bestellen

Disease Stage Strongly Modulates Responsiveness to Targeted Agents in Nf1 Mutant Mice with Myeloprolfierative Disease (MPD) and Acute Myeloid Leukemia (AML) von Lauchle, Jennifer O., Le, Doan, Kim, Doris, Tran, Mary, Peterson, Abigail, Przybranowski, Sally, Parada, Luis, Wolff, Linda, Leopold, Judith, Shannon, Kevin M.

Volltext